Carregant...
Chemopreventive efficacy of the cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, is predicted by adenoma expression of Cox-2 and 15-PGDH
BACKGROUND: The APC trial showed that cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, decreased adenoma development in patients at high risk for colorectal cancer. A prospectively planned analysis of the APC trial tested the hypothesis that expression of target enzymes in adenomas removed before begi...
Guardat en:
| Publicat a: | Cancer Epidemiol Biomarkers Prev |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519921/ https://ncbi.nlm.nih.gov/pubmed/29769213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-17-0573 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|